8 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Landmark investment aligns with Thailand 4.0 strategy, driving exports, jobs, and health innovation Sirio Pharma, the world’s largest contract developer and manufacturer of nutraceuticals, today announced the start of construction on its first manufacturing site in Thailand, as well as its first Asian facility outside China. The $40 million state-of-theart site in Chonburi will cover approximately 60,000 sqm and is expected to be fully operational by 2027. The new smart factory will be among the most advanced nutraceutical facilities globally, integrating automated production lines, robotics, AI-driven process controls, and sustainable energy systems. This investment represents a major step forward in Thailand’s 4.0 strategy, strengthening the nation’s reputation as a hub for high-value, high-tech manufacturing and enhancing its export competitiveness in the fast-growing global nutraceutical market. Beyond infrastructure, the project will create high-skilled local jobs in manufacturing, quality, and R&D, while providing training in advanced production technologies. The site will also serve as a center of collaboration with Thai universities and local suppliers, supporting innovation across the country’s health and wellness sector. “This investment is not just about a new factory — it is about creating a long-term partnership with Thailand,” said Alex Du, General Manager, Asia Pacific BU at Sirio Pharma. “Thailand offers exceptional talent, advanced infrastructure, and a strategic location in the heart of Southeast Asia. Our Chonburi site will be one of the most advanced nutraceutical plants globally — featuring smart factory technologies, integrated R&D capabilities, and our proprietary formulation platforms. Together with local partners, we aim to help position Thailand as the leading regional hub for health and nutrition innovation, boosting exports and giving Thai brands a platform to reach global markets.” The facility will supply both domestic and international customers, contributing to Thailand’s net trade surplus and supporting the country’s ambition to become a regional leader in wellness and functional foods. Sirio currently operates seven facilities worldwide – in the EU, USA, and China – making Chonburi its eighth global site. This expansion strengthens the company’s ability to offer localized production and faster time-tomarket, especially for customers in Southeast Asia where demand for nutraceuticals has surged — with Sirio’s APAC revenues (excluding China) growing 77% year-on-year. The project will be formally unveiled during Vitafoods Asia in Bangkok, where Sirio will also host its first APAC Future Forum, bringing together over 150 industry stakeholders to discuss growth opportunities and strategies to help Thai brands expand internationally. NEWS Sirio Pharma invests $40M in first thai manufacturing site to Thailand’s role as a global nutraceutical hub
RkJQdWJsaXNoZXIy MjY2OTA4MA==